8c77: Difference between revisions

m Protected "8c77" [edit=sysop:move=sysop]
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Unreleased structure'''


The entry 8c77 is ON HOLD
==Human cathepsin L after reaction with the thiocarbazate inhibitor CID 16725315==
<StructureSection load='8c77' size='340' side='right'caption='[[8c77]], [[Resolution|resolution]] 1.70&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[8c77]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8C77 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8C77 FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.7&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene>, <scene name='pdbligand=TXH:~{tert}-butyl+~{N}-[(2~{S})-3-(1~{H}-indol-3-yl)-1-(2-methanoylhydrazinyl)-1-oxidanylidene-propan-2-yl]carbamate'>TXH</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8c77 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8c77 OCA], [https://pdbe.org/8c77 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8c77 RCSB], [https://www.ebi.ac.uk/pdbsum/8c77 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8c77 ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CATL1_HUMAN CATL1_HUMAN] Important for the overall degradation of proteins in lysosomes.
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Emerging RNA viruses, including SARS-CoV-2, continue to be a major threat. Cell entry of SARS-CoV-2 particles via the endosomal pathway involves cysteine cathepsins. Due to ubiquitous expression, cathepsin L (CatL) is considered a promising drug target in the context of different viral and lysosome-related diseases. We characterized the anti-SARS-CoV-2 activity of a set of carbonyl- and succinyl epoxide-based inhibitors, which were previously identified as inhibitors of cathepsins or related cysteine proteases. Calpain inhibitor XII, MG-101, and CatL inhibitor IV possess antiviral activity in the very low nanomolar EC(50) range in Vero E6 cells and inhibit CatL in the picomolar K(i) range. We show a relevant off-target effect of CatL inhibition by the coronavirus main protease alpha-ketoamide inhibitor 13b. Crystal structures of CatL in complex with 14 compounds at resolutions better than 2 A present a solid basis for structure-guided understanding and optimization of CatL inhibitors toward protease drug development.


Authors: Falke, S., Lieske, J., Guenther, S., Reinke, P.Y.A., Ewert, W., Loboda, J., Karnicar, K., Usenik, A., Lindic, N., Sekirnik, A., Chapman, H.N., Hinrichs, W., Turk, D., Meents, A.
Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors.,Falke S, Lieske J, Herrmann A, Loboda J, Karnicar K, Gunther S, Reinke PYA, Ewert W, Usenik A, Lindic N, Sekirnik A, Dretnik K, Tsuge H, Turk V, Chapman HN, Hinrichs W, Ebert G, Turk D, Meents A J Med Chem. 2024 May 9;67(9):7048-7067. doi: 10.1021/acs.jmedchem.3c02351. Epub , 2024 Apr 17. PMID:38630165<ref>PMID:38630165</ref>


Description: Human cathepsin L after reaction with the thiocarbazate inhibitor CID 16725315
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[Category: Unreleased Structures]]
</div>
[[Category: Lieske, J]]
<div class="pdbe-citations 8c77" style="background-color:#fffaf0;"></div>
[[Category: Hinrichs, W]]
== References ==
[[Category: Usenik, A]]
<references/>
[[Category: Sekirnik, A]]
__TOC__
[[Category: Meents, A]]
</StructureSection>
[[Category: Ewert, W]]
[[Category: Homo sapiens]]
[[Category: Chapman, H.N]]
[[Category: Large Structures]]
[[Category: Turk, D]]
[[Category: Chapman HN]]
[[Category: Lindic, N]]
[[Category: Ewert W]]
[[Category: Karnicar, K]]
[[Category: Falke S]]
[[Category: Loboda, J]]
[[Category: Guenther S]]
[[Category: Falke, S]]
[[Category: Hinrichs W]]
[[Category: Guenther, S]]
[[Category: Karnicar K]]
[[Category: Reinke, P.Y.A]]
[[Category: Lieske J]]
[[Category: Lindic N]]
[[Category: Loboda J]]
[[Category: Meents A]]
[[Category: Reinke PYA]]
[[Category: Sekirnik A]]
[[Category: Turk D]]
[[Category: Usenik A]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA